Remedium Bio, Inc., a leader in genetic medicine, has announced a significant multi-target research and development partnership with Eli Lilly and Company ("Lilly") aimed at advancing gene therapies for Type 2 diabetes and obesity. Utilizing Remedium's Prometheus™ dose-adjustable gene therapy platform, this collaboration seeks to create long-acting therapeutics that can effectively manage these metabolic conditions.

The partnership will harness Lilly's extensive knowledge in metabolic diseases alongside Remedium's proprietary subcutaneous gene delivery system. This collaboration is designed to develop and commercialize one-time treatments that provide tunable control over therapeutic protein expression, ensuring multi-year efficacy.

"We are thrilled to collaborate with Lilly, a global leader in metabolic disease therapeutics, to bring durable, tunable therapies to patients living with Type 2 diabetes and obesity," said Frank Luppino, CEO of Remedium Bio. "This collaboration validates the potential of the Prometheus™ platform to transform the patient experience and expands its reach to one of the world's largest therapeutic markets."

As part of the agreement, Remedium Bio will receive an upfront payment, along with equity investments and potential milestone payments linked to development and commercialization. Additionally, Remedium is set to receive tiered royalties on worldwide net sales of any resulting products.

Remedium Bio is committed to addressing significant unmet clinical needs through innovative biotechnology. Their groundbreaking gene therapy platform offers safe and effective delivery of therapeutic genes, allowing for straightforward post-treatment dose adjustments. The Prometheus™ platform replaces a wide range of subcutaneously administered protein treatments with a single injection, adjustable dose gene therapy, significantly reducing the costs associated with traditional protein-based therapies. The company's pipeline includes several disease-modifying treatments that show remarkable efficacy in endocrinology, immunology, neurology, and musculoskeletal diseases.

Based in Lilly Gateway Labs, Boston, Remedium is part of the Lilly Catalyze360™ model, which supports early-stage biotech startups across various therapeutic areas by providing access to funding, top-tier laboratory space, and drug development expertise through its three pillars: Lilly Ventures, Lilly Gateway Labs®, and Lilly ExploR&D™.